Your browser doesn't support javascript.
loading
CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition.
Quijada-Álamo, Miguel; Hernández-Sánchez, María; Alonso-Pérez, Verónica; Rodríguez-Vicente, Ana E; García-Tuñón, Ignacio; Martín-Izquierdo, Marta; Hernández-Sánchez, Jesús María; Herrero, Ana B; Bastida, José María; San Segundo, Laura; Gruber, Michaela; García, Juan Luis; Yin, Shanye; Ten Hacken, Elisa; Benito, Rocío; Ordóñez, José Luis; Wu, Catherine J; Hernández-Rivas, Jesús María.
Afiliação
  • Quijada-Álamo M; University of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center, Salamanca, Spain.
  • Hernández-Sánchez M; Department of Hematology, University Hospital of Salamanca, Salamanca, Spain.
  • Alonso-Pérez V; University of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center, Salamanca, Spain.
  • Rodríguez-Vicente AE; Department of Hematology, University Hospital of Salamanca, Salamanca, Spain.
  • García-Tuñón I; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.
  • Martín-Izquierdo M; Broad Institute of Harvard and MIT, Cambridge, MA, 02142, USA.
  • Hernández-Sánchez JM; University of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center, Salamanca, Spain.
  • Herrero AB; Department of Hematology, University Hospital of Salamanca, Salamanca, Spain.
  • Bastida JM; University of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center, Salamanca, Spain.
  • San Segundo L; Department of Hematology, University Hospital of Salamanca, Salamanca, Spain.
  • Gruber M; University of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center, Salamanca, Spain.
  • García JL; Department of Hematology, University Hospital of Salamanca, Salamanca, Spain.
  • Yin S; University of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center, Salamanca, Spain.
  • Ten Hacken E; Department of Hematology, University Hospital of Salamanca, Salamanca, Spain.
  • Benito R; University of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center, Salamanca, Spain.
  • Ordóñez JL; Department of Hematology, University Hospital of Salamanca, Salamanca, Spain.
  • Wu CJ; University of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center, Salamanca, Spain.
  • Hernández-Rivas JM; Department of Hematology, University Hospital of Salamanca, Salamanca, Spain.
Leukemia ; 34(6): 1599-1612, 2020 06.
Article em En | MEDLINE | ID: mdl-31974435
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica / Mutagênese Sítio-Dirigida / Proteínas Mutadas de Ataxia Telangiectasia Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica / Mutagênese Sítio-Dirigida / Proteínas Mutadas de Ataxia Telangiectasia Idioma: En Ano de publicação: 2020 Tipo de documento: Article